Countdown Event
Keynote speeches by Lonza & Startup Founders| BioIncubate Application Info | Networking, Food and Apéro by Sprüngli
The countdown clock begins for the Bioincubate proposal deadline.
Join our countdown event for three exciting keynote talks in biotech, including a talk by the LONZA Head of R&D Biologics regarding innovation in biomanufacturing and talks from two entrepreneurial founders: Cofounder/CSO of Versantis (ETH Spin-off) & Cofounder/CEO of EraCal Therapeutics (UZH/Harvard Spin-off).
Further details on the BioIncubate program will be described including expectations for applicants.
Event followed by an apéro kindly sponsored by Sprüngli.
When? September 27, 6:30-8pm
Where? ETH HG D1.1.
What? BioIncubate application tips, keynotes speeches from experts in industry & entrepreneurship, networking, and free food/drinks!
All are welcome, regardless of whether you have an idea or a team. The only prerequisite is an excitement for innovation!
Keynote Speakers
Atul Mohindra
Head of R&D Biologics | Lonza
Atul joined Lonza in 2005 and currently is Head of R&D Biologics. Atul has over 20 years experience in cell biology, bioprocessing and media optimisation. His academic background includes a PhD in Molecular and Cell Biology, Institute for Cancer Research, University of Sheffield and BSc Honours in Pharmacology, University of Leeds.
Vincent Forster
CSO & Co-Founder | Versantis (ETH spin-off)
Vincent is an entrepreneur with deep scientific roots, performing his PhD in Pharmaceutical Sciences at ETH Zurich and subsequently working on a Pioneer Fellowship. In 2015 he co-founded Versantis, an ETH spin-off developing a highly innovative dialysis technology capable of removing diverse harmful compounds from an intoxicated patient. With its novel versatile approach, Versantis will answer crucial medical needs in the support of liver diseases such as metabolic disorders, cirrhosis, and hepatic failure. Vincent served as CEO/CSO - helping lead the company’s growth toward a successful acquisition by GENFIT in 2022 for a total consideration of up to CHF 105M.
Josua Jordi
CEO & Co-founder | EraCal Therapeutics Ltd (UZH & Harvard spin-off)
Josua founded the biotech-company EraCal Therapeutics Ltd., a spin-off of the University of Zurich and Harvard University, which develops first-in-class drugs to treat different diseases and conditions like obesity. Josua performed his Master’s in Biochemistry at ETH and completed a Ph.D. in physiology at the University of Zurich. He developed EraCal’s platform as a postdoctoral fellow at Harvard University.
Recently, EraCal Therapeutics was featured among Switzerland's most promising startups by Venturelab.